We are live on ! Find out more
ATXI

Avenue Therapeutics, Inc. Common Stock
ATXI

Delisted

ATXI was delisted on the 18th of March, 2025.

Back to rankings

9 hedge funds and large institutions have $407K invested in Avenue Therapeutics, Inc. Common Stock in 2024 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 1

141% more capital invested

Capital invested by funds: $169K → $407K (+$238K)

31% less funds holding

Funds holding: 13 → 9 (-4)

50% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 8

Holders
9
Holders Change
-4
Holders Change %
-30.77%
% of All Funds
0.13%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
4
Reduced
1
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
+$436K
2
SM
Sabby Management
Florida
+$165K
3
TRCT
Tower Research Capital (TRC)
New York
+$17.9K
4
UBS Group
UBS Group
Switzerland
+$3.91K
5
Bank of America
Bank of America
North Carolina
+$41

Top Sellers

Rank Fund Capital Flow
1
TSS
Two Sigma Securities
New York
-$26.3K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$10.6K
3
Geode Capital Management
Geode Capital Management
Massachusetts
-$7.69K
4
Vanguard Group
Vanguard Group
Pennsylvania
-$6.83K
5
HF
HRT Financial
New York
-$6K
Name Holding Trade Value Shares
Change 		Change in
Stake
AC
1
Armistice Capital
New York
$263K +$436K +75,000 New
SM
2
Sabby Management
Florida
$131K +$165K +28,448 +318%
TRCT
3
Tower Research Capital (TRC)
New York
$11.2K +$17.9K +3,087 +2,616%
UBS Group
4
UBS Group
Switzerland
$2.36K +$3.91K +673 New
Wells Fargo
5
Wells Fargo
California
$214 -$17 -3 -5%
EL
6
EMFO LLC
Florida
$28 +$6 +1 +14%
Bank of America
7
Bank of America
North Carolina
$24 +$41 +7 New
JP Morgan Chase
8
JP Morgan Chase
New York
$4 +$6 +1 New
TSS
9
Two Sigma Securities
New York
– -$26.3K -2,374 Closed
Susquehanna International Group
10
Susquehanna International Group
Pennsylvania
– -$10.6K -959 Closed
Geode Capital Management
11
Geode Capital Management
Massachusetts
– -$7.69K -695 Closed
Vanguard Group
12
Vanguard Group
Pennsylvania
– -$6.83K -617 Closed
HF
13
HRT Financial
New York
– -$6K -616 Closed
State Street
14
State Street
Massachusetts
– -$4.51K -408 Closed
Jane Street
15
Jane Street
New York
– -$4.42K -399 Closed
Millennium Management
16
Millennium Management
New York
– -$1.55K -140 Closed
Royal Bank of Canada
17
Royal Bank of Canada
Ontario, Canada
– +$6 +1 +14%

ATXI Hedge Fund Activity: Q2 2024 in Review

9 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Avenue Therapeutics, Inc. Common Stock (ATXI) for Q2 2024, worth a combined $407K — up 141% from $169K a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of ATXI and 4 opened new positions — a net loss of 4 holders — while 1 trimmed existing stakes and 4 added.

The largest buyer was Armistice Capital, opening a new position worth an estimated $436K. The largest seller was Two Sigma Securities, exiting entirely with an estimated $26.3K sold.

  • 9 institutional investors held Avenue Therapeutics, Inc. Common Stock (ATXI) as of Q2 2024, down from 13 in Q1 2024.
  • Funds reported $407K of Avenue Therapeutics, Inc. Common Stock stock for Q2 2024, up 141% quarter-over-quarter.
  • 4 funds opened new Avenue Therapeutics, Inc. Common Stock positions in Q2 2024 and 8 closed out, a net change of -4 holders.
  • The largest Avenue Therapeutics, Inc. Common Stock buyer in Q2 2024 was Armistice Capital, an estimated $436K added.
  • The largest Avenue Therapeutics, Inc. Common Stock seller in Q2 2024 was Two Sigma Securities, an estimated $26.3K sold.

Based on aggregated 13F filings for Q2 2024.